title: Procainamide: a perspective on its value and danger.
abstract: Procainamide remains one of the most widely used antiarrhythmic agents in clinical practice. Currently, it is widely used alone or in combination with class I agents (eg, mexiletine or tocainide) to prevent recurrent ventricular tachycardia or symptomatic nonsustained ventricular tachycardia. Procainamide is also used for short-term treatment of ventricular tachycardia and a variety of supraventricular tachycardias, primarily atrial flutter and atrial fibrillation. Long-term procainamide therapy is limited by a number of systemic side effects, primarily lupus-like syndrome, gastrointestinal disturbances, and autoimmune blood dyscrasias. Procainamide levels can be useful in initial dose titrations; however, QRS and QT interval measurements help prevent drug toxicity. It is recommended that patients being started on antiarrhythmic therapy with procainamide be admitted to the hospital for monitoring to ensure that their QT interval is not excessively prolonged.
authors.affiliation: Department of Medicine, Medical College of Virginia, Richmond 23298.
authors.forename: K A
authors.initials: KA
authors.lastname: Ellenbogen
authors.forename: M A
authors.initials: MA
authors.lastname: Wood
authors.forename: B S
authors.initials: BS
authors.lastname: Stambler
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000145:classification; D004562:Electrocardiography; D006801:Humans; D011342:Procainamide / Q000009:adverse effects* / Q000627:therapeutic use*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D017180:Tachycardia, Ventricular / Q000188:drug therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D011342:Procainamide